PRISMA 2009 Checklist

Section/topic	Item No	Checklist item	Reported on Page Number/Line Number	Reported on Section/Paragraph
TITLE				
Title	1	Identify the report as a systematic review, meta-analysis, or both.	line 1-3	Paragraph 1
ABSTRACT				
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	line 18-34	Paragraph 2
INTRODUCTION				
Rationale	3	Describe the rationale for the review in the context of what is already known.	line 38-39	Paragraph 3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	line 40-75	Paragraph 4
METHODS				
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	line 78-84	Paragraph 5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	line 97-102	Paragraph 7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	line 78-84	Paragraph 5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	line 87-102	Paragraph 6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	line 104-111	Paragraph 8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	line 113-118	Paragraph 9
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	line 113-118	Paragraph 9

Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	line 120-131	Paragraph 10
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	line 120-131	Paragraph 10
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	line 120-131	Paragraph 10
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	line 120-131	Paragraph 10
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	line 120-131	Paragraph 10
RESULTS				
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	line 134-146	Paragraph 11
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	line 148-157	Paragraph 12
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	line 159-165	Paragraph 13
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	line 167-173	Paragraph 14
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	line 175-188	Paragraph 15-16
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	line 190-195	Paragraph 17
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	line 197-202	Paragraph 18
DISCUSSION				
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	line 205-257	Paragraph 19-20
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	line 2592-68	Paragraph 21
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	line 270-279	Paragraph 22

FUNDING				
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	line 284	Paragraph 23

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Article information: http://dx.doi.org/10.21037/tcr-20-2035
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.